Introduction
Advances in the surgical, interventional and pharmacological treatment of patients with acute coronary syndromes have improved long-term clinical outcomes including quality of life (QoL). Moreover, novel therapeutic strategies are beneficial for patients with stable coronary artery disease (CAD) and large myocardial ischemic burden [1] [2] [3] . Nevertheless, as a consequence of an aging population, the number of individuals with severe coronary atherosclerosis not amendable for conventional revascularization continues to increase [4] . In many patients, despite optimal medical therapy, chronic myocardial ischemia is associated with debilitating anginal pain, which adversely influences QoL. Persistent ischemic chest discomfort is related to a higher rehospitalization rate [5] , mortality and morbidity [6, 7] . Transendocardial delivery of autologous and allogeneic stem/ progenitor cells is a promising alternative treatment option for patients diagnosed with refractory angina. Noteworthly, Rodrigo et al. [8] have also indicated an important economic aspect that this therapy is proving to reduce system resources of healthcare utilization. However, previously published data showed inconsistent results in regard to stem cell effectiveness. Studies with unselected mononuclear cells demonstrated a beneficial impact on angina symptoms and improvement of myocardial perfusion [9] [10] [11] . Conversely, the PROGENITOR trial enrolling refractory angina patients, who underwent transendocardial CD133+ cells injection, did not confirm previous observations [12] . Thus, additional studies are needed to evaluate and establish an optimal treatment strategy. In addition, factors such as patient selection criteria, cell types and route of administration should all be taken into consideration.
In the present study, QoL and the severity of chest pain in no-option angina patients treated with transendocardial autologous bone marrow-derived CD133+ cells were evaluated as the REGENT--VSEL trial sub-analysis (NCT01660581, www. clinicaltrials.gov) [13] .
Methods
REGENT-VSEL, a single center, randomized, double-blinded, placebo-controlled study, was coordinated by an independent Clinical Research Organization (www.kcri.pl), which provided a randomization system using sealed envelopes. Randomization was performed in the hematology center before cell/placebo processing on 1:1 basis. The study protocol and baseline characteristics are described in the previous publication [13] . Briefly, patients with refractory angina pectoris despite optimal medical therapy and were disqualified from further revascularization procedures were enrolled in the study.
Inclusion criteria
Inclusion criteria were as follows: 1) stable angina in Canadian Cardiovascular Society (CCS) II-IV class despite maximum pharmacotherapy for at least 2 weeks since the prior medication change; 2) presence of ≥ 1 myocardial segment with reversible ischemia in qualifying Tc-99m single photon emission computed tomography (SPECT); 3) disqualified from further revascularization by an independent Heart Team; 4) age > 18 and < 75 years and 5) written informed consent.
Exclusion criteria
Exclusion criteria were as follows: 1) acute coronary syndrome ≤ 6 months; 2) heart failure New York Heart Association (NYHA) III-IV class; 3) left ventricular (LV) ejection fraction (LVEF) < 35%; 4) contraindications to NOGA procedure (ventricular wall thickness < 8 mm, intracardiac thrombus, severe aortic stenosis, LV an aneurysm or severe peripheral artery disease precluding vascular access); 5) previous implantation of cardioverter-defibrillator or pacemaker; 6) history of malignancy; 7) active infection; 8) life expectancy less than 6 months; 9) bleeding diathesis; 10) renal insufficiency (GFR < 30 mL/min/1.73 m 2 ) and 11) pregnancy, lactation, or lack of adequate contraception in women of childbearing potential. 
End-points
Based on the REGENT-VSEL trial, the following end-points were evaluated in this sub-analysis: QoL and change in the angina severity (CCS class) assessed at baseline and during outpatient followup visits at 1, 4, 6, 12 months after cell/placebo application.
Endocardial mapping and intramyocardial injection
NOGA-XP 3D electro-mechanical system (Biosense Webster, Johnson&Johnson, Diamond Bar, CA, USA) was applied for endocardial mapping (200-250 valid points collected) and intramyocardial application. In the active group, patients received autologous CD133+ bone marrow (BM)-derived stem cells (mean number of 3.2 ± 2.4 × 10 6 ). In the placebo group, patients received 0.9% NaCl with the addition of 10% donor serum. The region of interest was determined based on NOGA-XP electromechanical parameters defining hibernating areas (an abnormal mechanical function with viable myocardium). A median of 10 trans-endocardial cell/placebo injections (200 µL per application) were performed with a comparable mean volume in both groups.
Clinical status and QoL assessment
During hospitalization and scheduled outpatient follow-up visits at 1, 4, 6, 12 months after cell/placebo delivery: (1) severity of angina was assessed according to the CCS scoring system, grading chest pain symptoms from I to IV and (2) QoL as measured using the Seattle Angina Questionnaire (SAQ) ranging from 0% to 100% [14] . The SAQ quantifies five categories: physical limitation (PL), angina stability (AS), angina frequency (AF), treatment satisfaction (TS) and quality of life score (QOLs).
Participant treatment allocations were double-blinded during hospitalization and during the whole follow-up period. Moreover, the principal investigator was blinded in regard to QoL questionnaires filled out by patients during outpatient clinic visits.
The REGENT-VSEL study was approved by the Ethics Committee of the Medical University of Silesia in Katowice and Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products. The trial is in accordance with the Declaration of Helsinki.
Statistical analysis
Categorical variables were presented as numbers and percentages. Continuous variables were expressed as the mean ± standard deviation (SD) or median and interquartile range (IQR). Differences between groups were compared using the Student or Welch t-test depending on equality of variances for normally distributed variables. The Mann-Whitney U test was used for non-normally distributed continuous variables and ordinal data. The Shapiro-Wilk test assessed normal distribution of variables. Equality of variances was assessed using the Levene test. P values < 0.05 were considered statistically significant. All calculations were done with JMP ® , Version 13.1.0 SAS Institute Inc., Cary, NC.
Results
Out of 90 patients screened, 31 individuals (63.0 ± 6.4 years, 70% male) were enrolled in the study and were randomly assigned to an active treatment group receiving CD133+ cells (n = 16) or placebo group (n = 15). There were no significant differences in the distribution of baseline characteristics and pharmacotherapy between the study groups ( Table 1) .
The occurrence of peri-procedural serious adverse events (SAE) was noted in 2 patients allocated to the active group: (1) acute back pain in the lumbar area radiating to the abdomen during the mapping procedure, which was related to previously diagnosed spondyloarthritis and was fully resolved after analgesic treatment, (2) pseudoaneurysm of the femoral artery.
Clinical parameters
Clinical assessment was carried out at baseline and after 1, 4, 6 and 12 months in an outpatient setting.
There were no cases of death or of myocardial infarction (MI) noted during outpatient follow-up visits. Two SAEs occurred in the placebo-treated group, (unstable angina: treated medically; deep vein thrombosis) and one SAE in the active group which was a hospital admission for unstable angina and was treated conservatively.
Repeated measure analysis of CCS changes within groups showed no significant differences: p = 0.63 and p = 0.32 in stem cell and placebo group, respectively (Fig. 1A, B) . Overall differences across the repeated measures of CCS in the total population was observed (p = 0.04), but did not vary across study groups (p = 0.38). (Fig. 2) . Furthermore, there was a statistically significant inter-group difference in QOLs at month 1 and 4 (p = 0.04) -QOLs improved in the placebo group with no change in treatment (Table 2) .
One-year evaluation of PL, AS, AF and TS showed similar results between the two groups. Table 3 shows PL score measured during consecutive follow-up visits. In comparison to baseline, PL increased in both control and treatment groups throughout the first year of follow-up. A statistically significant difference was observed between month 1 and 6 (p = 0.03). The PL score decreased in the treatment group but improved in the placebo group. There was no difference detected between the two groups in the AS and AF scores (Table 4 and  Table 5 , respectively). Analysis of TS, presented in Table 6 , showed a statistically non-significant trend towards inter-group difference between month 1 and 4 as well as between month 1 and 6 post stem cell/placebo treatment.
Discussion
In accordance with previously published studies, the REGENT-VSEL trial showed that intramyocardial application of autologous stem cells is safe and feasible [9] [10] [11] 15] . However, the main finding of the present sub-analysis is that transendocardial application of autologous BM-derived CD133+ stem cells in patients with chronic refractory angina did not show significant improvement in the QoL and CCS class within 12 month follow-up. Similarly, in the PROGENITOR trial [12] Previously published trials with refractory angina patients treated with BM-and PB-derived mononuclear cells (MNC) produced promising overall results. The vast majority of studies presented a reduction of angina frequency in short-and long-term (5 years) follow-up [10, 11, 15, [17] [18] [19] [20] [21] . In the RE-INJECT AP trial [17] , NOGA-based intramyocardial application of 100 × 10 6 BM-MNC was performed improving QoL and CCS class with increased myocardial perfusion during the first and second (after 4.6 ± 2.5 years) cell injections. Moreover, Rodrigo et al. [18] observed similar clinical effects in patients who had had placebo injections in the past, and who had received 100 × 10 6 of MNC during the trial. Interestingly, in the REGENT-VSEL and RE-INJECT AP trials, no increase in LVEF was observed. On the contrary, patients enrolled in the PROTECT-CAD, who received low (1 × 10 6 ) or high (2 × 10 6 ) dose of MNC showed an increase of LVEF [10] with CCS reduction in the active and placebo group. Moreover, in studies by Beers et al. [19] Table 5 . Seattle Angina Questionnaire -angina frequency (AF) category. MNC on myocardium may be associated with the heterogeneity of the injected cell population. Currently, there is no evidence to support the use of immune-selected cells (CXCR4 or CD133) over non-selected BM-MNC in patients with stable CAD or MI. In the IMPACT-CABG [22] and CARDIO133 [23] trials, CD133/CD34/CD45 triple-positive, and CD133+ cells, respectively, were injected transepicardially during a coronary artery bypass grafting procedure showing no advantage over placebo in patients with ischemic cardiomyopathy. On the contrary, Stamm et al. [24] used CD133+ cells in the same group of patients and reported improved perfusion with a significant increase in LVEF at 3-year follow-up. Interestingly, intracoronary delivery of autologous BM-derived CD133+/CD34+ cells in patients with ischemic heart diseases and a history of MI (3-6 months before enrolment), proved to have a beneficial effect on myocardium by improving perfusion and reducing the scar area [25] . Furthermore, the clinical applicability of intracoronary delivered immune-selected cells was evaluated in patients with recent MI showing improved LV function [26, 27] . On the contrary, those results were not confirmed in the TIME trial including ST-segment elevation MI patients treated with percutaneous coronary intervention and subsequent intracoronary administration of unselected BM-MNC [28] .
As presented above, the results of published studies are incoherent. Thus, it is crucial to determine the characteristics of patients who respond to cell therapy. According to individual SPECT analysis from the REGENT-VSEL and a study by Rodrigo et al. [29] , patients with a higher number of abnormal perfusion segments at baseline tended to have more significant improvement after cell application. Multivariate analysis indicates that allocation to an active group increased the chance of positive response to cell treatment by 3.5-times, and with a history of MI by 1.5-times. Moreover, diabetes was also associated with a significant response to BMC therapy [29] .
The presented data suggests that application of immuno-selected CD133 cells is not optimal for angina symptom treatment in patients with chronic myocardial ischemia.
Limitations of the study
Since the study was stopped prematurely due to slow patient enrollment, it may be considered underpowered. Thus, sub-analysis results should be interpreted with caution.
Conclusions
Findings support the feasibility and safety of transendocardial injection of CD133+ cells in patients with refractory angina. The present study waslimited by a low number of patients and did not demonstrate a significant improvement in QoL or angina pectoris symptoms in patients receiving cell therapy.
